Last reviewed · How we verify
NCT04556266
A Phase I Trial of Donor- Derived 19-28z CAR T Cells Following Allogeneic Transplant for the Treatment of CD19 Malignancies
Phase 1 trial testing CAR T-Cell Infusion in Leukemia. Withdrawn.
1 March 2022
Quick facts
| Lead sponsor | Memorial Sloan Kettering Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Start date | 1 July 2021 |
| Primary completion | 1 March 2022 |
| Estimated completion | 1 March 2022 |
| Sites | 1 location across United States |
Drugs / interventions tested
- CAR T-Cell Infusion
Conditions studied
- Leukemia — all drugs for Leukemia →
- Lymphoma — all drugs for Lymphoma →
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
Sponsor
Memorial Sloan Kettering Cancer Center — full company profile →
Who can join
Adults 18 to 60, any sex, with Leukemia or Lymphoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purposed of this study is to determine whether an infusion with specialized 'modified T cells' (or CD19 chimeric antigen T cells, also called CD19 CAR T cells) that target the B cell marker will reduce the risk of relapse after transplant.
Publications & conference data
5 peer-reviewed publications reference this trial (live from Europe PMC):
-
Recent updates on allogeneic CAR-T cells in hematological malignancies.
Mansoori S, Noei A, Maali A, Seyed-Motahari SS, et al · · 2024 · cited 34× · PMID 39227937 · DOI 10.1186/s12935-024-03479-y -
Reduced-intensity conditioning hematopoietic stem cell transplantation for chronic lymphocytic leukemia and Richter's transformation.
Lahoud OB, Devlin SM, Maloy MA, Roeker LE, et al · · 2021 · cited 21× · PMID 34297048 · DOI 10.1182/bloodadvances.2020003726 -
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Pytlik R, Polgarova K, Karolova J, Klener P. · · 2020 · cited 14× · PMID 33260966 · DOI 10.3390/vaccines8040708 -
Emerging frontiers in immuno- and gene therapy for cancer.
Gustafson MP, Ligon JA, Bersenev A, McCann CD, et al · · 2023 · cited 13× · PMID 36280438 · DOI 10.1016/j.jcyt.2022.10.002 -
[Universal chimeric antigen receptor T cells therapy: current status and future perspectives].
Huang Y, Hu KJ, Hu YX, Huang H. · · 2021 · cited 1× · PMID 34753238 · DOI 10.3760/cma.j.issn.0253-2727.2021.09.015
Verify or expand the search:
- PubMed search for NCT04556266
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Leukemia
Currently open trials in the same condition.
- NCT07405424 — Spiritual Care Intervention in Adult Patients Diagnosed With Acute Leukemia · NA · recruiting
- NCT07249346 — Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease ( · Phase 2 · recruiting
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT06856226 — Natural History Study to Determine Drug Metabolism Phenotype and Appropriate Germline Source DNA in Patients Undergoing · recruiting
- NCT07148180 — A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: · Phase 1, PHASE2 · recruiting
Other Memorial Sloan Kettering Cancer Center trials
Trials by the same sponsor.
- NCT07566377 — Cord Blood Transplantation in Children and Young Adults With Blood Cancer · Phase 2 · recruiting
- NCT07507643 — A Study of Methylprednisolone in People Having Liver Surgery · Phase 3 · recruiting
- NCT07483307 — A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Breast Cancer · Phase 2 · recruiting
- NCT07459673 — HERizon-Breast: A ctDNA-Guided Adaptive Study of Sequential Anti-HER2 Therapies and CNS Prophylaxis to Induce Long-Term · Phase 2 · recruiting
- NCT07449195 — A Study Comparing Two Optical Coherence Tomography Devices in People With Ocular Tumors · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04556266 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Memorial Sloan Kettering Cancer Center
- Last refreshed: 13 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04556266.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing